Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Timed Sequential Busulfan and Post Transplant Cyclophosphamide for Allogeneic Transplantation

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT02861417
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:24.797107+00:00
Published At
2026-02-17T00:00:00+00:00
Record Updated At
2026-02-17
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Hematopoietic and Lymphoid Cell Neoplasm", "High Risk Acute Myeloid Leukemia", "High Risk Myelodysplastic Syndrome", "Lymphoproliferative Disorder", "Myelodysplastic Syndrome", "Myelodysplastic/Myeloproliferative Neoplasm", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Acute Myeloid Leukemia", "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Recurrent High Risk Myelodysplastic Syndrome", "Recurrent Hodgkin Lymphoma", "Recurrent Myelodysplastic Syndrome", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Plasma Cell Myeloma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-02-17"
protocolSection.identificationModule.nctId
"NCT02861417"
protocolSection.identificationModule.officialTitle
"Timed Sequential Busulfan and Post Transplant Cyclophosphamide for Allogeneic Transplantation"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Hematopoietic and Lymphoid Cell Neoplasm (protocolSection.conditionsModule.conditions)
  • High Risk Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
  • High Risk Myelodysplastic Syndrome (protocolSection.conditionsModule.conditions)
  • Lymphoproliferative Disorder (protocolSection.conditionsModule.conditions)
  • Myelodysplastic Syndrome (protocolSection.conditionsModule.conditions)
  • Myelodysplastic/Myeloproliferative Neoplasm (protocolSection.conditionsModule.conditions)
  • Recurrent Acute Lymphoblastic Leukemia (protocolSection.conditionsModule.conditions)
  • Recurrent Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
  • Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive (protocolSection.conditionsModule.conditions)
  • Recurrent High Risk Myelodysplastic Syndrome (protocolSection.conditionsModule.conditions)
  • Recurrent Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Myelodysplastic Syndrome (protocolSection.conditionsModule.conditions)
  • Recurrent Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Plasma Cell Myeloma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.